InnoPharmax Inc.

Taipei, Taiwan

InnoPharmax Inc.

Taipei, Taiwan

Time filter

Source Type

Patent
Innopharmax inc. | Date: 2014-03-05

A composition of entacapone comprising entacapone or pharmaceutically acceptable salts, PVPK30 and SDS is disclosed in the present invention, wherein the mass ratio of entacapone : PVPK30 : SDS is 1:0.05~0.6:0.06~0.1. The present invention also discloses preparative method and use of the composition of entacapone.


A self micro-emulsifying oral pharmaceutical composition of a hydrophilic drug or its pharmaceutical acceptable salt and the preparation method thereof are disclosed. The composition comprises hydrophilic drug such as bendamustine or gemcitabine, solvent, surfactant and hydrophilic carrier, and has good bioavailability and stability. Said hydrophilic carrier is compatible with drug solution and surfactant.


Patent
Innopharmax Inc. and Tsh Biopharm Corporation Ltd. | Date: 2010-09-29

A controlled release carvedilol formulation for less frequent, preferably once daily administration is described. The controlled release formulation comprises a therapeutically effective amount of carvedilol or a pharmaceutically acceptable salt thereof, a matrix forming polymer, a solubility enhancer and a pharmaceutically acceptable carrier. In one embodiment, a controlled release formulation having a therapeutically effective amount of carvedilol is contained in two or more subunits having different release profiles. The controlled release formulation is usable in the treatment and/or prophylaxis of one or more conditions such as cardiovascular disorders.


Patent
TSH Biopharm Corporation Ltd. and Innopharmax inc. | Date: 2012-07-04

A controlled release carvedilol formulation for less frequent, preferably once daily administration is described. The controlled release formulation comprises a therapeutically effective amount of carvedilol or a pharmaceutically acceptable salt thereof, a matrix forming polymer, a solubility enhancer and a pharmaceutically acceptable carrier. In one embodiment, a controlled release formulation having a therapeutically effective amount of carvedilol is contained in two or more subunits having different release profiles. The controlled release formulation is usable in the treatment and/or prophylaxis of one or more conditions such as cardiovascular disorders.


Patent
Innopharmax Inc. | Date: 2011-04-26

A composition of entacapone comprising entacapone or pharmaceutically acceptable salts, PVPK30 and SDS is disclosed in the present invention, wherein the mass ratio of entacapone: PVPK30: SDS is 1:0.05-0.6:0.06-0.1. The present invention also discloses preparative method and use of the composition of entacapone.


Patent
Innopharmax Inc. | Date: 2010-11-15

A preparation process of (6R)-tetrahydrobiopterin hydrochloride is provided, which comprises hydrogenating L-biopterin in the presence of a catalyst of Pt group metal in the basic substrate containing solvent, potassium hydroxide and potassium dihydrogen phosphate to obtain (6R)-tetrahydrobiopterin hydrochloride, wherein the pH value of the basic substrate is controlled by potassium hydroxide and potassium dihydrogen phosphate in the range of about 10 to about 13.


A pharmaceutical composition used to treat Parkinsons disease contains levodopa, carbidopa and entacapone or pharmaceutically acceptable salt thereof, and at least one kind of pharmaceutically acceptable excipients. Entacapone is not mixed with levodopa or carbidopa in the pharmaceutical composition. The preparation method of the pharmaceutical composition includes making the first particles with levodopa and carbidopa, making the second particles with entacapone, and then pressing the two kinds of particles into tablets


A self micro-emulsifying oral pharmaceutical composition of a hydrophilic drug or its pharmaceutical acceptable salt and the preparation method thereof are disclosed. The composition comprises hydrophilic drug such as bendamustine or gemcitabine, solvent, surfactant and hydrophilic carrier, and has good bioavailability and stability. Said hydrophilic carrier is compatible with drug solution and surfactant.


Patent
Innopharmax inc. | Date: 2013-08-21

A preparation process of (6R)-tetrahydrobiopterin hydrochloride is provided, which comprises hydrogenating L-biopterin in the presence of a catalyst of Pt group metal in the basic substrate containing solvent, potassium hydroxide and potassium dihydrogen phosphate to obtain (6R)-tetrahydrobiopterin hydrochloride, wherein the pH value of the basic substrate is controlled by potassium hydroxide and potassium dihydrogen phosphate in the range of about 10 to about 13.


The present invention provides an oral self micro-emulsifying pharmaceutical composition of a hydrophilic drug or a pharmaceutically acceptable salt thereof which, in addition to the hydrophilic drug, one or more solvents for solving the hydrophilic drug to form a drug-solvent solution and a surfactant system, further comprises one or more hydrophilic carrier which are compatible with said drug-solvent solution and the surfactant system. The oral self micro-emulsifying pharmaceutical composition of the invention exhibits comparative bioavailability to that of the hydrophilic drug through injection and is stable during storage. A method for preparing the oral self micro-emulsifying pharmaceutical composition is also provided.

Loading InnoPharmax Inc. collaborators
Loading InnoPharmax Inc. collaborators